机构：[1]Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen 361003, People’s Republic of China.[2]Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, People’s Republic of China.临床科室其他部门放疗科华南肿瘤学国家重点实验室中山大学肿瘤防治中心[3]Department of Gastrointestinal Surgery, Xiamen Cancer Hospital, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
Background: To investigate the clinical value of preoperative and postoperative radiotherapy (RT) in patients with rectal signet-ring cell carcinoma (SRCC). Methods: Using the Surveillance, Epidemiology, and End Results program patients with stage II-III rectal SRCC were retrospectively included between 1988 and 2012. Univariate and multivariate Cox regression analyses were performed to analyze the effect of preoperative and postoperative RT on cause-specific survival (CSS). Results: A total of 292 patients were included: 138 patients received preoperative RT, 101 patients received postoperative RT, and 53 patients underwent surgery alone. Overall, 5- and 10-year CSS was 43.8 and 37.6%, respectively. Preliminary survival analysis demonstrated that preoperative RT improved CSS versus surgery alone, especially in patients with stage III disease. Multivariate analysis demonstrated that preoperative RT was independent predictors for CSS in stage III rectal SRCC. CSS in preoperative and postoperative RT groups was comparable. Conclusions: Preoperative RT significantly improved survival outcomes in patients with stage III rectal SRCC.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|3 区医学
小类|3 区核医学4 区肿瘤学
最新[2023]版：
大类|2 区医学
小类|2 区核医学3 区肿瘤学
第一作者：
第一作者机构：[1]Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen 361003, People’s Republic of China.
共同第一作者：
通讯作者：
通讯机构：[2]Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, People’s Republic of China.[3]Department of Gastrointestinal Surgery, Xiamen Cancer Hospital, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
